TxCell SA (TXCL):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:TxCell SA (TXCL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7601
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Txcell SA (Txcell) is a biotechnology company that develops and innovates cell-based immunotherapy utilizing antigen specific regulatory T-cells. The company provides pipeline products such as car-treg transplantation, car-treg lupus, car-treg dermatology, ovasave and col-treg. It offers products for chronic inflammatory diseases including crohn’s disease, autoimmune uveitis and central nervous system inflammatory diseases. Txcell utilizes proprietary technology platform, antigen specific treg for inflammation and autoimmunity that uses the immuno-modulatory properties of peripheral blood antigen-specific Type 1 regulatory T cells or Ag-Treg, for recognizing an antigen that is present at the target site of inflammation. The company partners with pharmaceutical companies, biotechnology companies and institutions to develop technology platforms. Txcell is headquartered in Valbonne, France.

TxCell SA (TXCL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
TxCell SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TxCell SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TxCell SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TxCell SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
TxCell SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
TxCell SA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
TxCell Secures USD21.36 Million in Venture Funding 11
TxCell Raises US$16.1 Million In Third Round Of Financing 12
Partnerships 13
TxCell Enters into R&D Agreement with Inserm Transfert 13
TxCell Enters into Research Agreement with University of British Columbia 14
TxCell Enters into R&D Agreement with Lubeck Institute of Experimental Dermatology 15
TxCell Enters into Research Agreement with Ospedale San Raffaele 16
Licensing Agreements 17
TxCell Exercises Option for Licensing Agreement with Yeda Research and Development 17
TxCell Enters into Licensing Agreement with Ferring International for Ovasave 18
Equity Offering 20
TxCell Raises USD11.8 Million in Rights Offering of Shares and Warrants 20
TxCell Raises USD8.3 Million in Private Placement of Shares 22
TxCell Completes IPO 23
Debt Offering 25
TxCell to Raise up to USD5.6 Million in Private Placement of Notes 25
Acquisition 26
Sangamo Therapeutics Acquires TxCell 26
TxCell SA – Key Competitors 28
TxCell SA – Key Employees 29
TxCell SA – Locations And Subsidiaries 30
Head Office 30
Recent Developments 31
Financial Announcements 31
Jul 19, 2018: TxCell: financial information for the 2nd quarter of 2018 31
Mar 14, 2018: TxCell 2017 financial results and 2018 objectives 32
Jan 24, 2018: TxCell announces 4th quarter 2017 financials and participation at upcoming scientific conferences 35
Oct 19, 2017: TxCell: financial information for the 3rd quarter of 2017 36
Sep 21, 2017: TxCell first-half 2017 financial results and strategy update 37
Jul 26, 2017: TxCell: Financial Information for The 2nd Quarter of 2017 39
Product News 40
12/18/2017: TxCell Completes CAR-Treg Manufacturing Process Development and Provides Update to CMO Selection 40
10/02/2017: TxCell to present two posters at ESGCT 2017 41
Clinical Trials 42
Jun 21, 2018: TxCell: First in vivo proof-of-concept data with CD8+ CAR-Treg presented at FOCIS 2018 42
Sep 26, 2017: TxCell Collaboration Presents New Proof-of-Concept Transplantation Results with Proprietary Second-Generation CAR-Tregs 43
Sep 13, 2017: TxCell: Presentation of New Transplantation CAR-Treg Data at ESOT 2017 44
Other Significant Developments 45
Sep 19, 2018: TxCell announces first-half 2018 financial results 45
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
TxCell SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
TxCell SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TxCell SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TxCell SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TxCell SA, Deals By Therapy Area, 2012 to YTD 2018 9
TxCell SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
TxCell Secures USD21.36 Million in Venture Funding 11
TxCell Raises US$16.1 Million In Third Round Of Financing 12
TxCell Enters into R&D Agreement with Inserm Transfert 13
TxCell Enters into Research Agreement with University of British Columbia 14
TxCell Enters into R&D Agreement with Lubeck Institute of Experimental Dermatology 15
TxCell Enters into Research Agreement with Ospedale San Raffaele 16
TxCell Exercises Option for Licensing Agreement with Yeda Research and Development 17
TxCell Enters into Licensing Agreement with Ferring International for Ovasave 18
TxCell Raises USD11.8 Million in Rights Offering of Shares and Warrants 20
TxCell Raises USD8.3 Million in Private Placement of Shares 22
TxCell Completes IPO 23
TxCell to Raise up to USD5.6 Million in Private Placement of Notes 25
Sangamo Therapeutics Acquires TxCell 26
TxCell SA, Key Competitors 28
TxCell SA, Key Employees 29

List of Figures
TxCell SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
TxCell SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
TxCell SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
TxCell SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
TxCell SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TxCell SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
TxCell SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TxCell SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[TxCell SA (TXCL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Chiesi USA Inc-製薬・医療分野:企業M&A・提携分析
    Summary Chiesi USA Inc (Chiesi USA), a specialty pharmaceutical company, is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A. The company researches, develops, produces and commercializes innovative products in the areas such as cardiovascular, respiratory, neonatology, rare disease and specia …
  • Dermapharm AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Dermapharm AG (Dermapharm) is a pharmaceutical company that offers dermatological and allergy medicines. The company offers products for allergies, disinfection and wound treatment, skin and hair care, corticoids, minerals, osteoporosis, fungal infections, vaginal thrush, other preparations, …
  • Hotel Croatia Cavtat:企業の戦略・SWOT・財務分析
    Hotel Croatia Cavtat - Strategy, SWOT and Corporate Finance Report Summary Hotel Croatia Cavtat - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Ascendant Group Limited (AGL.BH):企業の戦略的SWOT分析
    Ascendant Group Limited (AGL.BH) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Tocagen Inc (TOCA):製薬・医療:M&Aディール及び事業提携情報
    Summary Tocagen Inc (Tocagen) is a clinical-stage cancer-selective gene therapy company that develops and commercializes product candidates for the treatment of cancer. The company offers lead product candidate such as Toca 511 and Toca FC, which is being investigated for the treatment of recurrent …
  • Folksam:企業のM&A・事業提携・投資動向
    Folksam - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Folksam Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • PTT Exploration and Production Public Co Ltd (PTTEP):石油・ガス:M&Aディール及び事業提携情報
    Summary PTT Exploration and Production Public Company Limited (PTTEP), a subsidiary of PTT Public Company Limited, is an oil and gas company. It carries out exploration, development and production of hydrocarbons. The company manages an array of exploration projects in different stages and producing …
  • ACWA Power Barka SAOG (APBS):企業の財務・戦略的SWOT分析
    ACWA Power Barka SAOG (APBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Indeck Energy Services Inc:発電所・企業SWOT分析
    Indeck Energy Services Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key em …
  • AB Science SA (AB)-製薬・医療分野:企業M&A・提携分析
    Summary AB Science SA (ABS) is a pharmaceutical company that discovers, develops and commercializes tyrosine kinase inhibitor. The company concentrates its research on inflammatory diseases, cancers and central nervous system diseases in human and veterinary medicine. Its masitinib is an orally admi …
  • BioClinica Inc:医療機器:M&Aディール及び事業提携情報
    Summary BioClinica Inc (BioClinica), formerly Bio-Imaging Technologies, Inc., is a clinical trials services provider. The company’s cloud-based offerings comprise medical image management solutions; electronic data capture (EDC) solutions; clinical data management; clinical trial management systems …
  • Ecsponent Ltd (ECS):企業の財務・戦略的SWOT分析
    Ecsponent Ltd (ECS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • National Institutes of Health:企業のM&A・事業提携・投資動向
    National Institutes of Health - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's National Institutes of Health Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Krka, d. d., Novo mesto:企業の戦略・SWOT・財務分析
    Krka, d. d., Novo mesto - Strategy, SWOT and Corporate Finance Report Summary Krka, d. d., Novo mesto - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Enel SpA (ENEL):企業の財務・戦略的SWOT分析
    Enel SpA (ENEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Wellington Pub Company PLC:企業の戦略・SWOT・財務情報
    Wellington Pub Company PLC - Strategy, SWOT and Corporate Finance Report Summary Wellington Pub Company PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • NLC India Ltd (NLCINDIA):電力:M&Aディール及び事業提携情報
    Summary NLC India Limited (NLCIL), formerly Neyveli Lignite Corporation Limited, a Government of India Enterprise, is a mining and power generation company. It operates opencast lignite mines and sources coal to generate electricity. The company generates electricity by using various sources of ener …
  • Bsquare Corporation (BSQR):企業の財務・戦略的SWOT分析
    Bsquare Corporation (BSQR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Saudi Electricity Co:発電所・企業SWOT分析
    Saudi Electricity Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employee …
  • Meyer Burger Technology AG (MBTN):企業の財務・戦略的SWOT分析
    Meyer Burger Technology AG (MBTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆